- Home
- ENLV
as 12-18-2024 2:35pm EST
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
| Founded: | 2005 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 25.9M | IPO Year: | 1995 |
| Target Price: | $9.50 | AVG Volume (30 days): | 462.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.97 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $4.59 | Next Earning Date: | 11-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Enlivex Therapeutics Ltd. News
ENLV Breaking Stock News: Dive into ENLV Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
6 days ago
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial
MT Newswires
7 days ago
Enlivex Therapeutics Gets Approval for Phase 1 Trial of Allocetra to Treat Osteoarthritis
GlobeNewswire
7 days ago
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
GlobeNewswire
13 days ago
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
ACCESSWIRE
22 days ago
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Barrons.com
a month ago
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000
GlobeNewswire
a month ago
Enlivex Announces the Dosing of the First Patient in a Phase I Clinical Trial Evaluating Allocetra in Patients with Psoriatic Arthritis
GlobeNewswire
a month ago
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Compare ENLV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ENLV Enlivex Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.